Active, not recruitingEarly Phase 1NCT03970226
Tocilizumab in Children With ACP
Studying Adamantinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Margaret Macy, MDChildren's Hospital Colorado
- Intervention
- Tocilizumab(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 2-21 years · All sexes
- Timeline
- 2019 – 2027
Study locations (1)
- Children's Hospital Colorado, Aurora, Colorado, United States
Collaborators
National Cancer Institute (NCI) · National Institutes of Health (NIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03970226 on ClinicalTrials.govOther trials for Adamantinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05919264FOG-001 in Locally Advanced or Metastatic Solid TumorsParabilis Medicines, Inc.
- RECRUITINGPHASE2NCT05286788MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaNationwide Children's Hospital
- RECRUITINGPHASE2NCT05233397ACTEMRA® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaNationwide Children's Hospital